Introduction
============

Gastric adenocarcinoma accounts for 40% of all new gastric cancer cases worldwide. It is the fifth most common cancer globally and the third most common cause of cancer-related deaths (estimated 723,000 deaths, 8.8% of the total in 2012),[@b1-ott-9-2455] mainly because of a late diagnosis. The disease is particularly prevalent in Far Eastern countries. Gastric adenocarcinoma is the most common malignancy in the People's Republic of China, and was the second leading cause of death by malignancy (14.33%) in 2012.[@b2-ott-9-2455] Gastric cancer patients have considerably lower survival rates than those with other gastroenterological tract cancers, except for cancer of the esophagus. Five-year survival rates of patients with localized disease (stages I, II, N0) (63.2%) decreased to 28.4% after the cancer spread to regional lymph nodes (stages II, III, N1--N3), and to 3.9% following the detection of distant metastases (stage IV).[@b3-ott-9-2455]

An early diagnosis coupled with good treatment strategy for gastric cancer can significantly improve the survival rates. Esophagogastroduodenoscopy is the most reliable method for diagnosis of gastric adenocarcinoma. It is used broadly in gastroscopy in the People's Republic of China, South Korea, and Japan because of the high incidence of gastric adenocarcinoma in these countries. South Korea and Japan are the only two countries that provide a government-sponsored screening program for gastric cancer. These resulted in low mortality-to-incidence ratio (0.43 in Japan, 0.35 in South Korea), indicating the benefits of population-based screening in high-prevalence regions.[@b1-ott-9-2455] The screening programs run in these countries include gastroscopy and serology tests. However, the feasibility and effectiveness of gastroscopy is questionable for the countries with low incidence rates for gastric cancers.

Hence, serum biomarkers that identify patients with high risk for gastric adenocarcinoma would increase the effectiveness of endoscopy and improve the early diagnosis rate. In past decades, studies have revealed several serum biomarkers for gastric cancer which comprise carcinoembryonic antigen, cancer antigen (CA) 19-9, and CA 72-4, among others. However, the sensitivity of these serum biomarkers used during diagnosis of gastric adenocarcinoma (20%--30%) is lower as compared to other cancers.[@b4-ott-9-2455]--[@b6-ott-9-2455] Resent proteomic-based research identified several significantly more selective and specific biomarkers.[@b7-ott-9-2455] Also, miRNAs are emerging as a new potentially important tool in diagnostics of gastric cancer.[@b8-ott-9-2455] These new approaches, however, often require specific technique and expensive instrumentation and cannot be used for routine screening tests.

Traditionally, the detection of serum markers was done using the enzyme-linked immunosorbent assay (ELISA). However, the disadvantage of this method is that it requires larger volumes of sample and incurs high costs compared to the recent method of multiplex detection. The Luminex^®^ xMAP^®^ technology enables the large numbers of biological tests to be conducted and analyzed quickly, cost-effectively, and accurately as compared to the ELISA tests.

In this study, we developed a diagnostic serum biomarker panel using Luminex multiplex technology and validated its performance by differentiating the patients with gastric adenocarcinoma from the healthy controls.

Materials and methods
=====================

Patient samples
---------------

During 2008--2010, serum samples were collected from patients (n=285) with newly diagnosed primary gastric adenocarcinoma without the presence of other cancers at The First Hospital of Jilin University, Changchun, People's Republic of China. All gastric cancer patients underwent radical tumor resection with histologically confirmed diagnosis of gastric adenocarcinoma. Control samples (n=238) were collected from attendees of the health check-up program from the same hospital between 2008 and 2010. Patients from the control group had no history of cancer. All participants underwent: 1) routine medical history and physical examination; 2) routine blood and *Helicobacter pylori* IgG tests; 3) chest X-ray; 4) abdominal ultrasound investigation or computed tomography scan; 5) gastroduodenoscopy; and 6) mammography in women. Two hundred and thirty-eight control samples without inflammatory conditions, or confirmed or suspected cancer that needed medical treatment, were included. All blood samples were collected before any medical treatment in the early morning. Peripheral blood was collected and stored in SST II tubes (BD, Franklin Lakes, NJ, USA) at room temperature for 1 hour, then centrifuged at 3,000× *g* for 5 minutes. Supernatants were collected, separated in aliquots, and stored at −80°C. All participants signed an informed consent form. The study was approved by the Institutional Review Board at The First Hospital of Jilin University.

Clinical data on demographics and pathological characteristics were available for all patients whose serum samples were used for this study ([Table 1](#t1-ott-9-2455){ref-type="table"}). The T status, N status, and TNM stage of each tumor were classified according to the seventh edition of the AJCC classification.[@b9-ott-9-2455]

Samples were randomly divided into two datasets. Serum samples from 228 patients with gastric adenocarcinoma and 190 control serum samples were grouped as a training set. Serum samples from 48 patients with gastric adenocarcinoma and 47 control serum samples were grouped as an independent validation set. Patient demographics and clinical profiles are presented in [Table 2](#t2-ott-9-2455){ref-type="table"}.

Construction of 9-plex bead array panel
---------------------------------------

The xMAP bead-based technology (Luminex Corp., Austin, TX, USA) permits simultaneous analysis of multiple analytes in a single run. It is an antibody-based microarray, with high sensitivity and high throughput advantage, which has been used extensively in clinical diagnosis and research work. Among the nine target proteins ([Table 3](#t3-ott-9-2455){ref-type="table"}) chosen for this project, COX2, ADAM8, and beta-catenin were identified in our previous studies.[@b10-ott-9-2455],[@b11-ott-9-2455] There was difference in the expression of beta-catenin between the gastric cancer tissue and normal gastric mucosa tissue. COX2 and ADAM8 were higher in the gastric cancer tissues with lymph node metastases than in those without metastasis. Serum pepsinogen I (PGI) and serum pepsinogen II (PGII), as well as PGI/PGII ratio were used in the screening of gastric cancer in the countries with high and moderate incidence rates, such as the People's Republic of China, Japan, and South Korea. Most studies have demonstrated that low concentrations of PGI and low PGI/PGII ratios in the serum or plasma are indicators of atrophic gastritis, which is linked to elevated risk of gastric cancer.[@b12-ott-9-2455]--[@b15-ott-9-2455] *H. pylori* and gastric atrophy have both been identified as etiological factors for gastric cancer. *H. pylori* was declared as a class I carcinogen by the International Agency for Research on Cancer in 1994.[@b16-ott-9-2455] Epidemiological surveys support a positive association between *H. pylori* infection and the development of gastric cancer.[@b17-ott-9-2455]--[@b19-ott-9-2455] In this study, all patients and health controls had been tested for *H. pylori* IgG with ELISA kit (Biohit ELISA kit; Biohit, Helsinki, Finland). Intercellular cell adhesion molecule (ICAM), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and hemoglobin were also associated with gastric cancer development and metastasis in previous studies.[@b20-ott-9-2455]--[@b26-ott-9-2455]

All antibodies have been validated in ELISA and were used according to the manufacturer's instructions. The antigen protein has been validated for ELISA too. We developed all kits for Luminex according to The Luminex Cookbook.[@b27-ott-9-2455] All nine protein kits were divided into a 5-plex panel and two 2-plex panels with different dilution rates for each patients' samples. All samples were randomly divided into different plates to perform the Luminex test. The random number allocation and grouping was done using STATA 12 software.

Multiplex assay procedure
-------------------------

Multiplex assay was performed on a COSTAR™ 96-well round bottom plate (Corning Incorporated, Corning, NY, USA). Standard curve samples and prediluted patient samples (50 µL) were dispensed into the wells. Capture antibody-beads mixtures (50 µL) were added into each well and incubated at room temperature for 2 hours. Next, magnetic beads were suspended in 50 µL of 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), then 50 µL of detection antibodies with biotin were added to each well and the mixtures incubated at room temperature for 2 hours. Finally, 100 µL of streptavidin-phycoerythrin (4 µg/mL) were added and the mixtures incubated at room temperature for 30 minutes. Each step was followed by a double washing step using 1% BSA in PBS (Sigma-Aldrich Co., St Louis, MO, USA) on the magnetic plate (Alpaqua Engineering, LLC, Beverly, MA, USA). All incubations were done using the Digene Hybrid Capture System at 800 rpm.

Subsequent to the final washing step, samples were resuspended in 100 µL of 1% BSA in PBS and read using Luminex-200™ (Luminex Corp.). The standard curve was constructed using a seven-parametric-curve fitting, and the results were calculated using Xponent 3.1 (Luminex Inc.). Markers were grouped together according to the dilution factor after the cross-reactivity was checked across all analytes. During the experiment, intra-assay precision ranged from 2% to 16%, and interassay precision ranged from 6% to 19%. The acceptance criteria for each individual run followed the Westgard rule.[@b28-ott-9-2455]

Statistical analysis
--------------------

The raw data of biomarkers from Luminex combined with the *H. pylori* IgG concentrations were analyzed by comparison between the gastric cancer patients group and the control group using *χ*^2^, the *z*-statistic, and the Student's *t*-test. Further, the univariate and multivariate logistic regression analysis and correlations between biomarkers were analyzed. The analysis of correlations between biomarkers was performed as well. For the identification of algorithms distinguishing controls from patients with gastric carcinoma, three classification analysis methods -- random forest (RF), support vector machine (SVM), and logistic regression -- were performed with the R program package. The R project of statistical computing (Wirtschaftsuniversität, Wien, Austria) was used for classification analysis to develop the algorithms.

The RF ensemble learning method, proposed by Breiman, is a combination of tree predictors where each tree depends on the values of a random vector sampled independently and with the same distribution for all trees in the forest.[@b29-ott-9-2455] The idea behind SVMs is to construct a separating hyperplane or set of hyperplanes in a high or infinite dimensional space for classification.[@b30-ott-9-2455] After obtaining results with the training set, each classification algorithm with different groups of classifiers was cross-validated with the validation set. The prediction performances with accuracy (number of patients or controls identical to the result of the classification/examined total number), sensitivity, and specificity were analyzed. The receiver operating characteristic curves were constructed and the areas under the curves were calculated. A *P*-value of 0.05 was considered statistically significant.

Results
=======

The results of nine Luminex test biomarkers and the ELISA result of IgG to *H. pylori* are listed in [Table 4](#t4-ott-9-2455){ref-type="table"} for the gastric cancer group and the control group. With the exception of EGFR (*P*=0.1951) and ICAM (*P*=0.2627), there were significant statistical differences in the biomarkers' levels (*P*\<0.05). The levels of eight markers were higher in the gastric cancer group compared to the control group.

The correlation analysis for ten biomarkers showed that there were significant correlations between beta-catenin, COX2, and VEGF (*r*\>0.7 for all three pairs, [Table 5](#t5-ott-9-2455){ref-type="table"}).

Since ten proteins are too many to run a single algorithm, the feature selection process was performed using RF. This function shows the cross-validated prediction performance of models with sequentially reduced numbers of predictors (ranked by variable importance) via a nested cross-validation procedure ([Figure 1](#f1-ott-9-2455){ref-type="fig"}). The figure shows that five proteins (IgG to *H. pylori*, ADAM8, PGI, PGII, VEGF) are the best for the prediction. Biomarker selection is shown in [Table 6](#t6-ott-9-2455){ref-type="table"}, and the important scores are plotted in [Figure 2](#f2-ott-9-2455){ref-type="fig"}. The results for three classification analysis methods -- RF, SVM, and logistic regression -- are shown in [Table 7](#t7-ott-9-2455){ref-type="table"}. The receiver operating characteristics of RF, SVM, and logistic regression algorithm of the five biomarkers are shown in [Figure 3](#f3-ott-9-2455){ref-type="fig"}. In the test group, the accuracy of the RF and SVM algorithms for this five-biomarker panel was 82.5% and 86.1%, respectively, which was higher than the accuracy of logistic regression (78.7%).

The Cox model was used to model the relationship between the survival time, disease stage, and covariates, including the five proteins identified earlier. Conditional censoring distribution bootstrapping was used to construct the 95% confidence interval. The data show that proteins have no effect on survival time, while pathology N stage pN and pathology T stage pT had significant effect on survival ([Table 8](#t8-ott-9-2455){ref-type="table"}).

Discussion
==========

This study used Luminex and ELISA methods to identify ten serum biomarkers to distinguish between gastric cancer patients and healthy controls. Among the biomarkers included in the panel, eight biomarkers demonstrated statistically significant differences between the gastric cancer group and the healthy control group. Additionally, in this study we tested three proteins that we have earlier reported to have higher expression in the gastric cancer tissue compared to the normal gastric mucosa (beta-catenin), or higher expression in the gastric cancer tissue with metastases compared to the gastric cancer tissue without metastases (COX2, ADAM8).[@b10-ott-9-2455],[@b11-ott-9-2455] The levels of these three proteins were higher in the gastric cancer patients' serum than in the healthy controls. The proteomics studies provide the basics for high-sensitivity tests like the Luminex. In this study, using the computing algorithm combined with high-throughput method, we identified five biomarkers for gastric cancer among the ten selected proteins.

A number of research studies have been aimed toward identifying the early diagnostic biomarkers for gastric cancers in blood serum, gastric juice, and even in the exhalants from the lungs.[@b31-ott-9-2455]--[@b33-ott-9-2455] However, to date, there is no single known biomarker unique for diagnosis of gastric cancer. The traditional biomarkers such as carcinoembryonic antigen, CA 19-9, CA 12-5, and CA 7-24 are more sensitive in the diagnostics of other gastroenterological cancers rather than for gastric cancer.[@b4-ott-9-2455]--[@b6-ott-9-2455] For this reason, they were excluded from this study. Instead, we tried to test other proteins that are known to be associated with tumorigenesis and development of gastric cancer. We used three algorithms to combine five biomarkers (IgG to *H. pylori*, ADAM8, PGI, PGII, and VEGF) in a panel cross-validated in a training group of 418 samples and a test group of 105 samples. SVM and RF resulted in higher accuracy and sensitivity compared to the logistic regression method. For SVM, the accuracy, sensitivity, and specificity in the test group were 86.1%, 88.6%, and 83.2%, respectively. Both PGI and PGII are being used in the gastric cancer screening in the countries with high incidence of this disease. *H. pylori* infection is known to be a major cause of peptic ulcer development and, eventually, gastric cancer development in Asian countries. The infection rate and the carrier rate are higher in Asian populations than elsewhere in the world. With the *H. pylori* infection, gastric mucosa cells can produce more COX2, and beta-catenin is known to be involved in this process. In turn, COX2 and beta-catenin direct the production of VEGF. We detected significant correlation between protein levels of beta-catenin, COX2, and VEGF in our analysis. Moreover, VEGF and ADAM8 were associated with tumor metastases. Thus, the five selected biomarkers have a significant role to play during gastric carcinogenesis.

In this study, SVM algorithm demonstrated the best performance. It had the highest accuracy, sensitivity, and specificity as compared to RF and logistic regression analysis. The five selected biomarkers were not associated with the prognosis of gastric cancer patients. In addition, the overall sensitivity was sustained regardless of TNM stage and tumor size. Although none of the individual markers showed sufficient diagnostic power independently, the biomarker panel identified in this study performed well. SVM algorithm demonstrated the best performance in this study. The concentrations of proteins that we identified in this study are much higher than the concentrations of other cytokines and low level biomarkers that are usually detected with mass spectroscopy in serum samples. Therefore, the panel of biomarkers may have clinical applications and can be particularly useful for the preliminary diagnostics in patients with reported symptoms.

Conclusion
==========

Using three diagnostic algorithms -- RF, SVM, and logistic regression -- we created and validated a panel of biomarkers that might prove useful in the clinical diagnostics and/or screening of gastric cancer. The panel includes five biomarkers: IgG to *H. pylori*, ADAM8, PGI, PGII, and VEGF. Among the diagnostic algorithms, SVM out-performed the others regardless of TNM stage or tumor size. In future, the developed panel of biomarkers may supplement clinical gastroscopic evaluation of symptomatic patients and enhance diagnostic accuracy.
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###### 

Demographic data and pathological characteristics of patients with gastric cancer and healthy controls

                                Gastric adenocarcinoma, n=285   Control, n=238
  ----------------------------- ------------------------------- ----------------
  Age, years                    59.89±11.499                    59.14±9.33
  Sex                                                           
   Males                        204                             157
   Females                      81                              81
  Stage                                                         
   I                            66 (23.1%)                      
   II                           93 (32.6%)                      
   III                          126 (44.2%)                     
  Alcohol and smoking history                                   
   Alcohol                      86 −199                         
   Smoking                      130 −155                        
  Early stage                   48                              
  Advanced stage                237                             
  Differentiation type                                          
   High                         7                               
   Medium                       120                             
   Low                          158                             
  Tumor                                                         
   T1                           48                              
   T2                           55                              
   T3                           3                               
   T4                           179                             
  Lymph node                                                    
   N0                           120                             
   N1                           40                              
   N2                           47                              
   N3                           78                              
  Tumor ≤2 cm                   52                              
  Tumor \>2 cm                  233                             
  Tumor position                                                
   Antrum                       188                             
   Body                         65                              
   Cardia                       32                              

###### 

Patients' demographic data and clinical profiles in training and validation groups

               Training group   Validation group                 
  ------------ ---------------- ------------------ ------------- ------------
  Age, years   59.82±11. 32     59.15±9.27         60.14±10.73   59.11±7.93
  Sex                                                            
   Male        164              120                40            36
   Female      64               70                 17            12
  Stage                                                          
   I           47                                  19            
   II          78                                  15            
   III         103                                 23            

###### 

List of markers

  Biomarker                  Antigen         Capture antibody   Detection antibody
  -------------------------- --------------- ------------------ --------------------
  Growth/angiogenic factor                                      
   VEGF                      R&D System      R&D System         R&D System
   EGFR                      R&D System      R&D System         R&D System
  Coagulation/thrombosis                                        
   Hemoglobin                Sigma-Aldrich   Pierce             Pierce
  Adhesion                                                      
   ADAM8                     R&D System      R&D System         R&D System
   Beta-catenin              R&D System      R&D System         R&D System
   sICAM-1                   R&D System      R&D System         R&D System
  Inflammation                                                  
   COX2                      R&D System      R&D System         R&D System
  Pepsinogen                                                    
   Pepsinogen-I              R&D System      Abcam              Abcam
   Pepsinogen-II             Biohit          NOVUS              NOVUS

**Notes:** R&D System: R&D System Inc., Minneapolis, MN, USA; Sigma-Aldrich: Sigma-Aldrich Co., St Louis, MO, USA; Pierce:; Biohit: Biohit, Helsinki, Finland; Abcam: Abcam, MA, USA; NOVUS: Novus Biologicals, Littleton, CO, USA.

**Abbreviations:** ICAM, intercellular cell adhesion molecule; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; ADAM8, A Disintegrin And Metalloproteinase domain-containing protein 8.

###### 

The description of variables in gastric cancer patients and controls

  Variable                       --           Control (N=238)                       Gastric cancer (N=285)                Statistic   *P*-value
  ------------------------------ ------------ ------------------------------------- ------------------------------------- ----------- -----------
  IgG to *Helicobacter pylori*   Mean ± SD    35.14±37.98                           66.96±42.19                           *z*=8.90    \<0.0001
                                 M (Q1--Q3)   16.67 (6.31--60.64)                   66.44 (27.94--107.41)                             
                                 Min--Max     0.46--142.71                          0.60--155.67                                      
  PGI                            Mean ± SD    101.15±36.49                          4,740.89±22,768.80                    *z*=4.59    \<0.0001
                                 M (Q1--Q3)   94.05 (77.37--120.19)                 116.66 (74.28--211.51)                            
                                 Min--Max     13.54--286.47                         0.24--197,160.00                                  
  PGII                           Mean ± SD    13.96±9.98                            3,422.14±10,146.89                    *z*=9.12    \<0.0001
                                 M (Q1--Q3)   10.91 (7.38--17.38)                   21.66 (12.13--38.19)                              
                                 Min--Max     1.60--66.94                           0.14--90,759.61                                   
  PGI/PGII                       Mean ± SD    9.13±4.07                             5.71±4.07                             *z*=10.26   \<0.0001
                                 M (Q1--Q3)   8.56 (6.26--10.93)                    5.23 (3.03--7.61)                                 
                                 Min--Max     2.22--36.76                           0.04--24.49                                       
  Beta-catenin                   Mean ± SD    409.20±473.89                         767.73±854.38                         *z*=6.88    \<0.0001
                                 M (Q1--Q3)   269.98 (135.91--460.89)               483.61 (263.08--883.18)                           
                                 Min--Max     1.00--3,210.81                        1.00--5,456.21                                    
  COX2                           Mean ± SD    190.31±210.51                         308.00±320.50                         *z*=4.95    \<0.0001
                                 M (Q1--Q3)   146.60 (38.79--260.89)                221.51 (97.94--422.12)                            
                                 Min--Max     0.34--1,325.78                        1.00--2,481.92                                    
  ADAM8                          Mean ± SD    500.78±492.02                         1,146.98±1,161.13                     *z*=10.11   \<0.0001
                                 M (Q1--Q3)   337.12 (199.81--627.00)               803.82 (466.89--1,467.16)                         
                                 Min--Max     2.65--3,168.90                        1.00--9,645.67                                    
  VEGF                           Mean ± SD    242.79±277.96                         548.92±490.40                         *z*=10.23   \<0.0001
                                 M (Q1--Q3)   164.49 (77.28--290.32)                416.47 (236.06--707.36)                           
                                 Min--Max     1.00--1,962.88                        1.00--3,653.43                                    
  EGFR                           Mean ± SD    9,308.89±4,302.37                     9,837.98±5,024.02                     *t*=1.30    0.1951
                                 M (Q1--Q3)   8,211.83 (6,565.46--10,832.58)        9,029.69 (6,786.17--11,484.39)                    
                                 Min--Max     3,897.56--41,378.60                   1.00--47,739.98                                   
  ICAM                           Mean ± SD    174,870.10±86,585.45                  165,658.82±95,597.97                  *t*=1.15    0.2527
                                 M (Q1--Q3)   151,346.57 (119,159.57--213,194.11)   144,412.52 (107,495.51--200,256.92)               
                                 Min--Max     56,918.07--627,365.84                 1.00--1,101,730.81                                
  HB                             Mean ± SD    369,038.51±470,630.63                 939,135.01±3,663,960.29               *z*=2.42    0.0157
                                 M (Q1--Q3)   235,096.52 (135,491.09--417,276.58)   268,581.00 (144,175.20--724,694.68)               
                                 Min--Max     31,780.94--5,466,994.12               1.00--50,057,376.68                               

**Abbreviations:** HB, hemoglobin; M (Q1--Q3), median and interquartile range; Min--Max, minimum to maximum; PGI, serum pepsinogen I; PGII, serum pepsinogen II; SD, standard deviation; ICAM, intercellular cell adhesion molecule; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; ADAM8, A Disintegrin And Metalloproteinase domain-containing protein 8.

###### 

The results of correlation analysis for three variables

                 Beta-catenin                                        COX2                                                VEGF
  -------------- --------------------------------------------------- --------------------------------------------------- --------
  Beta-catenin   1.0000                                                                                                  
  COX2           0.8370[\*](#tfn4-ott-9-2455){ref-type="table-fn"}   1.0000                                              
  VEGF           0.7893[\*](#tfn4-ott-9-2455){ref-type="table-fn"}   0.7291[\*](#tfn4-ott-9-2455){ref-type="table-fn"}   1.0000

**Note:**

The correlation is statistically significant.

**Abbreviation:** VEGF, vascular endothelial growth factor.

###### 

Biomarker selection in the training group

  Marker                         Avg.imp
  ------------------------------ ---------
  ADAM8                          42.6065
  PGI                            38.7232
  PGII                           37.7563
  VEGF                           35.1600
  IgG to *Helicobacter pylori*   34.7993
  EGFR                           10.8508
  Beta-catenin                   10.3391
  HB                             8.4268
  ICAM                           6.8035
  COX2                           2.1472

**Abbreviations:** HB, hemoglobin; ICAM, intercellular cell adhesion molecule; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; ADAM8, A Disintegrin And Metalloproteinase domain-containing protein 8; PGI, serum pepsinogen I; PGII, serum pepsinogen II.

###### 

Diagnostic performance of classification algorithms with five-biomarker panel

             Training group   Test group                           
  ---------- ---------------- ------------ ------- ------- ------- -------
  RF         0.790            0.842        0.729   0.825   0.860   0.784
  SVM        0.838            0.877        0.792   0.861   0.886   0.832
  Logistic   0.762            0.807        0.708   0.787   0.829   0.737

**Abbreviations:** Logistic, logistic regression; RF, random forest; SVM, support vector machine.

###### 

Cox model coefficients and 95% confidence interval

                                 OR       2.5% OR   97.5% OR
  ------------------------------ -------- --------- -----------------
  ADAM8                          1.118    0.754     1.591
  PGI                            0.935    0.640     1.444
  PGII                           1.035    0.733     1.392
  VEGF                           1.077    0.795     1.541
  IgG to *Helicobacter pylori*   1.170    0.937     1.544
  N1                             0.726    0.000     2.086
  N2                             3.817    1.841     10.506
  N3                             5.998    3.110     15.813
  T1                             1.365    0.180     38,189,896.926
  T2                             15.098   0.000     789,835,105.698
  T3                             5.680    1.800     141,247,321.593
  T4                             11.395   2.777     391,254,179.091

**Abbreviations:** OR, odds ratio; PGI, serum pepsinogen I; PGII, serum pepsinogen II; VEGF, vascular endothelial growth factor; ADAM8, A Disintegrin And Metalloproteinase domain-containing protein 8.
